Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
L646246-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$41.90
|
|
|
L646246-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$83.90
|
|
|
L646246-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$133.90
|
|
|
L646246-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$268.90
|
|
| Synonyms | F77451 | Larazotide acetate | Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate | UNII-FO8S2IW40N | Larazotide acetate [USAN] | DTXSID401007986 | FO8S2IW40N | D09352 | Q25327025 | Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-gl |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be u |
| Storage Temp | Desiccated,Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Action Type | PARTIAL AGONIST |
| Mechanism of action | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist |
| Product Description |
Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection . In Vitro Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth. Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells. Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC 50 value of 82.5 μM. In Vivo Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HLA-HCD4/DQ8 double transgenic miceDosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels. Form:Solid IC50& Target:Paracellular permeability |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Peptides |
| Direct Parent | Oligopeptides |
| Alternative Parents | Leucine and derivatives Valine and derivatives Proline and derivatives N-acyl-alpha amino acids Alpha amino acid amides Pyrrolidinecarboxamides N-acylpyrrolidines N-acyl amines Tertiary carboxylic acid amides Secondary carboxylic acid amides Amino acids Primary carboxylic acid amides Azacyclic compounds Carboxylic acids Monocarboxylic acids and derivatives Hydrocarbon derivatives Carbonyl compounds Monoalkylamines Organic oxides |
| Molecular Framework | Not available |
| Substituents | Alpha-oligopeptide - Leucine or derivatives - Valine or derivatives - Proline or derivatives - N-acyl-alpha amino acid or derivatives - N-acyl-alpha-amino acid - Alpha-amino acid amide - N-substituted-alpha-amino acid - Alpha-amino acid or derivatives - N-acylpyrrolidine - Pyrrolidine carboxylic acid or derivatives - Pyrrolidine-2-carboxamide - N-acyl-amine - Fatty amide - Fatty acyl - Tertiary carboxylic acid amide - Pyrrolidine - Secondary carboxylic acid amide - Amino acid or derivatives - Amino acid - Primary carboxylic acid amide - Carboxamide group - Azacycle - Carboxylic acid - Organoheterocyclic compound - Monocarboxylic acid or derivatives - Primary aliphatic amine - Organic oxygen compound - Organic nitrogen compound - Carbonyl group - Hydrocarbon derivative - Amine - Organic oxide - Primary amine - Organooxygen compound - Organonitrogen compound - Aliphatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. |
| External Descriptors | Not available |
|
|
|
| IUPAC Name | acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid |
|---|---|
| INCHI | InChI=1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1 |
| InChIKey | NYGCNONRVCGHAT-UFIKZEAMSA-N |
| Smiles | CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)N1CCCC1C(=O)NCC(=O)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN.CC(=O)O |
| Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O |
| PubChem CID | 44146842 |
| Molecular Weight | 785.89 |
| Solubility | H2O : 16.67 mg/mL (21.21 mM; Need ultrasonic) DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming) |
|---|---|
| Molecular Weight | 785.900 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 21 |
| Exact Mass | 785.428 Da |
| Monoisotopic Mass | 785.428 Da |
| Topological Polar Surface Area | 339.000 Ų |
| Heavy Atom Count | 55 |
| Formal Charge | 0 |
| Complexity | 1320.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |